Literature DB >> 2957611

The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.

M R Hayden, J Hewitt, A J Stoessl, C Clark, W Ammann, W R Martin.   

Abstract

Twenty-three persons at risk for Huntington's disease (HD) have been studied using a polymorphic human linked DNA marker (D4S10) and positron emission tomography (PET). We determined the likelihood of inheritance of the gene for HD in 13 persons, using DNA polymorphism studies. Of these, eight persons had a greater than 90% probability of being presymptomatic heterozygotes for HD. Three of these eight subjects had caudate glucose utilization detected by PET that was more than 2 standard deviations (SD) below the age-matched control mean. Measurement of caudate glucose utilization in the other five presumed presymptomatic heterozygotes revealed results between 1 and 2 SD below the mean. Five persons had a less than 10% likelihood of having inherited the abnormal gene for HD. Of these, four had normal rates of glucose utilization in the caudate nuclei. However, one individual with DNA results indicating a low risk of developing HD had abnormally low measures of caudate glucose utilization. This suggests that a recombination had occurred between the linked marker and the gene in this person. These studies suggest that PET studies of caudate glucose utilization may help to confirm results of DNA studies in some persons, and may provide an opportunity to detect when DNA results may be incorrect due to recombination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2957611     DOI: 10.1212/wnl.37.9.1441

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  Measurement of caudate nucleus area--a more accurate measurement for Huntington's disease?

Authors:  J M Wardlaw; R J Sellar; L J Abernethy
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

Review 2.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 3.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

4.  SPECT, CT and MRI in a Turkish family with Huntington's disease.

Authors:  R P Bruyn; G Hageman; J A Geelen; F A van der Weel; A R Rozeboom; F Barkhof; P Scheltens
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

5.  Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography.

Authors:  T Kuwert; H W Lange; K J Langen; H Herzog; H Hefter; A Aulich; L E Feinendegen
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

Review 6.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

7.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Striatal hypometabolism in premanifest and manifest Huntington's disease patients.

Authors:  Diego Alfonso López-Mora; Valle Camacho; Jesús Pérez-Pérez; Saül Martínez-Horta; Alejandro Fernández; Frederic Sampedro; Alberto Montes; Gloria Andrea Lozano-Martínez; Beatriz Gómez-Anson; Jaime Kulisevsky; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

9.  Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease.

Authors:  T Kuwert; H W Lange; H Boecker; H Titz; H Herzog; A Aulich; B C Wang; U Nayak; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

10.  Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?

Authors:  Hyeeun Shin; Man Ho Kim; Su Jin Lee; Kyung-Han Lee; Mi-Jung Kim; Ji Sun Kim; Jin Whan Cho
Journal:  J Clin Neurol       Date:  2013-01-03       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.